OmniAb Shares Down 5.5 percent Time to Sell?
| OABI Stock | USD 3.35 0.07 2.05% |
Under 69% of OmniAb's investor base is looking to short. The analysis of the overall investor sentiment regarding OmniAb Inc suggests that many traders are alarmed. OmniAb's investing sentiment shows overall attitude of investors towards OmniAb Inc.
OmniAb |
OmniAb, Inc. s stock price dropped 5.5 percent during mid-day trading on Friday . The stock traded as low as 3.75 and last traded at 3.78. Approximately 101,346 shares traded hands during trading, a decline of 80 percent from the average daily volume of 501,356 shares. The stock had previously closed at 4.00.
Read at thelincolnianonline.com
 |
OmniAb Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards OmniAb can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
OmniAb Fundamental Analysis
We analyze OmniAb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OmniAb using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OmniAb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
OmniAb is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
OmniAb Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OmniAb stock to make a market-neutral strategy. Peer analysis of OmniAb could also be used in its relative valuation, which is a method of valuing OmniAb by comparing valuation metrics with similar companies.
Peers
OmniAb Related Equities
| BCAB | Bioatla | 6.67 | ||||
| IKNA | Ikena Oncology | 4.65 | ||||
| ERAS | Erasca | 3.13 | ||||
| LEGN | Legend Biotech | 3.03 | ||||
| ACET | Adicet Bio | 2.35 | ||||
| VRNA | Verona Pharma | 2.32 | ||||
| GLUE | Monte Rosa | 0.91 | ||||
| KROS | Keros Therapeutics | 0.18 | ||||
| OLMA | Olema Pharmaceuticals | 0.24 | ||||
| IDYA | Ideaya Biosciences | 1.78 | ||||
| ITOS | Iteos Therapeutics | 2.00 | ||||
| PMVP | Pmv Pharmaceuticals | 2.27 | ||||
| EWTX | Edgewise Therapeutics | 2.45 | ||||
| CGEM | Cullinan Oncology | 5.77 | ||||
| VOR | Vor Biopharma | 7.37 | ||||
| IPSC | Century Therapeutics | 10.29 | ||||
| PASG | Passage Bio | 10.42 |
Complementary Tools for OmniAb Stock analysis
When running OmniAb's price analysis, check to measure OmniAb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OmniAb is operating at the current time. Most of OmniAb's value examination focuses on studying past and present price action to predict the probability of OmniAb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OmniAb's price. Additionally, you may evaluate how the addition of OmniAb to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |